Published in Mol Cell Biol on May 01, 2005
Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells. Proc Natl Acad Sci U S A (2008) 2.33
T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2. J Exp Med (2006) 1.22
Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol (2006) 1.05
Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal (2011) 0.99
Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem (2009) 0.95
Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation. Mol Cell Biol (2011) 0.87
DOK2 inhibits EGFR-mutated lung adenocarcinoma. PLoS One (2013) 0.78
Reconstruction of explicit structural properties at the nanoscale via spectroscopic microscopy. J Biomed Opt (2016) 0.77
mRNA expression of DOK1-6 in human breast cancer. World J Clin Oncol (2014) 0.77
Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling. PLoS One (2015) 0.75
Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol (1997) 11.36
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem (1996) 10.08
Signaling through scaffold, anchoring, and adaptor proteins. Science (1997) 9.48
Dephosphorylation or antibody binding to the carboxy terminus stimulates pp60c-src. Mol Cell Biol (1986) 3.99
Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A (1999) 3.43
Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J (1996) 3.13
CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem (1991) 2.75
Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell (1997) 2.44
p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell (1997) 2.33
Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A (1995) 2.29
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res (2000) 2.14
Identification and characterization of cellular targets for tyrosine protein kinases. J Biol Chem (1983) 2.03
A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J (2000) 1.90
Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene (2001) 1.89
Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J (2003) 1.84
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med (2001) 1.73
Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol (2001) 1.71
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling. Mol Cell Biol (2000) 1.68
Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation. EMBO J (1993) 1.57
The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene (1998) 1.57
Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. J Cell Biol (2001) 1.52
Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem (2000) 1.48
Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem (1998) 1.48
Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev (2000) 1.48
c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun (1995) 1.44
A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Chem Biol (2002) 1.35
FRIP, a hematopoietic cell-specific rasGAP-interacting protein phosphorylated in response to cytokine stimulation. Immunity (1998) 1.31
Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci (1997) 1.28
Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. J Biol Chem (2002) 1.28
Characterization of a novel member of the DOK family that binds and modulates Abl signaling. Mol Cell Biol (1999) 1.28
Domain-dependent function of the rasGAP-binding protein p62Dok in cell signaling. J Biol Chem (2000) 1.28
Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. J Exp Med (2001) 1.19
Independent SH2-binding sites mediate interaction of Dok-related protein with RasGTPase-activating protein and Nck. J Biol Chem (1999) 1.19
Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr Biol (1999) 1.18
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. Oncogene (1995) 1.11
DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene (2001) 1.04
Downstream of kinase, p62(dok), is a mediator of Fc gamma IIB inhibition of Fc epsilon RI signaling. J Immunol (2002) 1.01
Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci U S A (2000) 1.00
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells. Oncogene (2002) 0.95
Transmembrane adapters: attractants for cytoplasmic effectors. Immunol Rev (2003) 0.94
Modulation of the protein tyrosine kinase activity and autophosphorylation of the epidermal growth factor receptor by its juxtamembrane region. Arch Biochem Biophys (1999) 0.93
Negative regulation of receptor tyrosine kinase signals. FEBS Lett (2001) 0.93
Epidermal growth factor-induced DNA synthesis. Key role for Src phosphorylation of the docking protein Gab2. J Biol Chem (2002) 0.89
Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites. J Cell Biol (2002) 0.88
Comparative study of three protein-tyrosine phosphatases. Chicken protein-tyrosine phosphatase lambda dephosphorylates c-Src tyrosine 527. J Biol Chem (1994) 0.88
Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. J Biol Chem (2003) 0.85
Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Oncogene (1999) 0.81
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Correlating structural dynamics and function in single ribozyme molecules. Science (2002) 5.16
Criteria for authorship in bioethics. Am J Bioeth (2011) 4.60
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Adult Asthma Consensus Guidelines update 2003. Can Respir J (2004) 3.61
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell (2008) 1.94
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.82
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res (2008) 1.78
Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner. Blood (2011) 1.73
Authorship policies of bioethics journals. J Med Ethics (2011) 1.63
Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther (2004) 1.62
Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol (2003) 1.48
Problems with co-funding in Canada. Science (2005) 1.48
The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem (2004) 1.47
Management of asthma in adults. CMAJ (2009) 1.43
Diagnosis of asthma in adults. CMAJ (2009) 1.41
Policies and initiatives aimed at addressing research misconduct in high-income countries. PLoS Med (2013) 1.41
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol (2013) 1.40
Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol (2008) 1.38
Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem J (2008) 1.37
Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer (2010) 1.36
The role of glypicans in mammalian development. Biochim Biophys Acta (2002) 1.33
Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med (2007) 1.33
Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem (2005) 1.32
The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. Semin Cell Dev Biol (2002) 1.31
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol (2012) 1.30
Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res (2007) 1.29
The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care (2011) 1.25
c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol (2009) 1.19
Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci (2006) 1.17
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol (2011) 1.14
The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood (2010) 1.12
Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood (2006) 1.11
Authorship ethics in global health research partnerships between researchers from low or middle income countries and high income countries. BMC Med Ethics (2014) 1.09
Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand. A novel mechanism of Anoikis of intestinal epithelial cells. J Biol Chem (2002) 1.08
Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol (2006) 1.07
A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene (2005) 1.07
ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem (2005) 1.07
'Plan of the day' adaptive radiotherapy for bladder cancer using helical tomotherapy. Radiother Oncol (2011) 1.05
A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol (2005) 1.04
Nonlinear multicontrast microscopy of hematoxylin-and-eosin-stained histological sections. J Biomed Opt (2010) 1.04
Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci (2014) 1.03
Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol (2011) 1.02
Vascular-specific growth factor angiopoietin 1 is involved in the organization of neuronal processes. J Comp Neurol (2005) 1.01
Enhanced expression of VEGF-A in β cells increases endothelial cell number but impairs islet morphogenesis and β cell proliferation. Dev Biol (2012) 1.01
A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol (2003) 1.00
Gamma Knife radiosurgery in the management of brainstem metastases. Clin Neurol Neurosurg (2013) 1.00
The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice. J Exp Med (2009) 0.98
Focused ultrasound-mediated bbb disruption is associated with an increase in activation of AKT: experimental study in rats. BMC Neurol (2010) 0.97
Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst (2007) 0.97
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat (2008) 0.97
Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am J Pathol (2005) 0.97
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg (2009) 0.96
Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo. Mech Dev (2005) 0.96
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol (2003) 0.96
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res (2002) 0.96
Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2. BMC Cell Biol (2007) 0.96
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells. Oncogene (2002) 0.95
Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires Notch signaling. Proc Natl Acad Sci U S A (2012) 0.95
Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res (2005) 0.94
Functional inhibition of secreted angiopoietin: a novel role for angiopoietin 1 in coronary vessel patterning. Biochem Biophys Res Commun (2004) 0.94
Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol (2008) 0.94
Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol (2012) 0.91
Embryonic vascular endothelial cells are malleable to reprogramming via Prox1 to a lymphatic gene signature. BMC Dev Biol (2010) 0.90
Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian hedgehog. EMBO Rep (2009) 0.90
Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease. Am J Pathol (2004) 0.90
Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 0.89
Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol (2006) 0.87
Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT. J Cancer Res Ther (2010) 0.86
Selective role of a distinct tyrosine residue on Tie2 in heart development and early hematopoiesis. Mol Cell Biol (2005) 0.86
Angiopoietin 1 expression levels in the myocardium direct coronary vessel development. Dev Dyn (2004) 0.86
Factors predictive of severity of osteoradionecrosis of the mandible. Head Neck (2011) 0.86
LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex. J Cell Sci (2012) 0.86
Concurrent chemoradiotherapy improves survival in patients with hypopharyngeal cancer. Int J Radiat Oncol Biol Phys (2011) 0.85
Tie2-dependent neovascularization of the ischemic hindlimb is mediated by angiopoietin-2. PLoS One (2012) 0.85
Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. J Biol Chem (2003) 0.85
Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Arch Otolaryngol Head Neck Surg (2008) 0.85
Regulation of bone morphogenetic protein signalling and cranial osteogenesis by Gpc1 and Gpc3. Bone (2013) 0.84
Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope (2004) 0.84
Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy. Breast Cancer Res (2010) 0.84
Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model. BMC Cancer (2014) 0.84
Immunohistochemical study of glypican 3 in thyroid cancer. Oncology (2008) 0.84
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys (2007) 0.84
Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation. Int J Radiat Oncol Biol Phys (2011) 0.84
XRP6258-induced gene expression patterns in head and neck cancer carcinoma. Laryngoscope (2010) 0.84
The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res (2014) 0.84
Dose variation during hypofractionated image-guided radiotherapy for prostate cancer: planned versus delivered. J Cancer Res Ther (2011) 0.83
The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytes. Cancer (2002) 0.82
Allergic rhinitis. Allergy Asthma Clin Immunol (2011) 0.82
A review of the key issues associated with the commercialization of biobanks. J Law Biosci (2014) 0.81
Oligomerized Tie2 localizes to clathrin-coated pits in response to angiopoietin-1. Histochem Cell Biol (2009) 0.80
Differential proteomic analysis of lymphatic, venous, and arterial endothelial cells extracted from bovine mesenteric vessels. Proteomics (2010) 0.80